A combination of the FLT3
kinase inhibitor quizartinib with 5 - azacitidine (AZA) or low - dose cytarabine (LDAC) is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.
A combination of the FLT3
kinase inhibitor quizartinib with 5 - azacitidine or low - dose cytarabine is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.